Sense Raises $50M Series B To Accelerate Launch Of Covid-19 Molecular Test On Its Veros™ Instrument-Free Product Platform

Sense Biodetection (Sense), today announced that it has raised a $50m Series B investment to advance commercialization of its VerosTM COVID-19 product and continue development of a portfolio of instrument-free, rapid molecular tests that enable improved access, outcomes, and value through patient-focused decentralized healthcare. The VerosTM platform introduces novel and proprietary rapid molecular amplification technology to detect a variety of deadly and costly diseases. The Series B round was led by Koch Disruptive Technologies (KDT), a subsidiary of Koch Industries, Inc.